Pfizer (NYSE:PFE) is one of those names where the headline narrative (COVID hangover, patent cliff) keeps overshadowing what ...

AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies ...

Last year, Pfizer invested around $9 billion in M&A deals, including the acquisition of Metsera and the licensing deal with ...

Pfizer reaffirmed its 2026 outlook, expecting full-year adjusted profit to come in between $2.80 and $3 per share, and ...

Pfizer Inc (NYSE:PFE, XETRA:PFE) reported first-quarter 2026 revenue and adjusted profit above Wall Street expectations on Tuesday, driven by strong growth in its launched and acquired products, as ...

Pfizer (PFE) posted Q3 revenue of $16.65B down 5.9% as COVID products declined sharply. Paxlovid dropped 55% and Comirnaty fell 20%. Teva (TEVA) delivered its 11th consecutive quarter of growth with ...

The payout ratio is over 100% for this high-yield healthcare giant, but don't run for the hills just yet.

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Pfizer Inc. (NYSE:PFE) has released its financial outlook for 2026, forecasting revenue in a range of $59.5 billion to $62.5 billion and adjusted diluted earnings per share between $2.80 and $3.00. At ...

Pfizer’s biggest competitors in the global pharmaceutical industry are Johnson & Johnson, Roche, Eli Lilly, AbbVie, Novo ...

Pfizer Inc. earns a Buy rating as the market overreacts to Q4's non-cash loss and conservative 2026 guidance, overlooking underlying operational strength. Excluding COVID-19 products, PFE posted 9% ...

Income investors usually don't mind too much if a stock doesn't deliver tremendous gains, as long as it keeps the dividends flowing. They typically don't like it when a stock tumbles, though, as ...